P
Protagonist Therapeutics
Develops orally-stable peptides to treat diseases that are currently addressed by injectable antibodies
About Protagonist Therapeutics
Protagonist Inc. is a clinical-stage biopharmaceutical company that focuses on peptide drug discovery and development. Their mission is to improve patients' lives by addressing areas of unmet need in both rare and prevalent diseases where current treatments are either limited or inadequate. They operate in the healthcare and pharmaceutical market, specifically in the area of drug discovery and development.
Their business model revolves around the discovery, development, and commercialization of peptide-based drugs. They conduct clinical trials to test the efficacy and safety of these drugs, with the ultimate goal of bringing them to market. Once a drug is approved for use, they generate revenue through its sale.
Protagonist Inc. is also committed to health equity and improving access to medicines. They ensure diverse representation in their clinical studies by actively seeking patients from various locations, age groups, and backgrounds. This includes a focus on including aging populations who are often left out of clinical studies.
In addition to their commitment to diverse patient representation, Protagonist Inc. also values diversity and inclusion within their workplace. They believe that a diverse and inclusive corporate culture is critical to their long-term success and innovation.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2016
Open roles
Protagonist Therapeutics in the Newark ecosystem
The Protagonist Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
National Institutes of Health
Series A6 investors entered at this stage
Starfish Ventures
Lilly Ventures- QBQIC BioVentures
Johnson & Johnson Development Corporation- IVInbio Ventures
Pharmstandard
Series B and later6 investors entered at this stage
Canaan
Foresite Capital
RA Capital Management
BVF Partners
Standard Treasury
Midcap Financial
Source: Dealroom Talent Intelligence.
Patents
48 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Protagonist Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
Takeda and Protagonist win first-in-class FDA approval for Mimrylo (rusfertide) in polycythemia vera
